Tolerability of outpatient antipsychotic treatment: 36-month results from the European Schizophrenia Outpatient Health Outcomes (SOHO) study

European Neuropsychopharmacology

Volumn 19, Issue 8, 2009, Pages 542-550

  Novick, Diego ^a,b   Haro, Josep Maria ^c   Perrin, Elena ^a   Suarez, David ^c   Texeira, João Marques ^d  

^a ELI LILLY AND COMPANY   (United States)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE SALUD MENTAL CIBERSAM   (Spain)

^d UNIVERSITY OF PORTO   (Portugal)

Author keywords

Atypical antipsychotic; Extrapyramidal side effects; Schizophrenia; Tolerability; Weight

Indexed keywords

AMISULPRIDE; CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE;

ADULT; AMENORRHEA; ARTICLE; CONTROLLED STUDY; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; GALACTORRHEA; GYNECOMASTIA; HUMAN; IMPOTENCE; LIBIDO DISORDER; MAJOR CLINICAL STUDY; MALE; OUTPATIENT CARE; PRIORITY JOURNAL; SCHIZOPHRENIA; SENSITIVITY ANALYSIS; SIDE EFFECT; TARDIVE DYSKINESIA; WEIGHT CHANGE; WEIGHT GAIN;

ADMINISTRATION, ORAL; ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BODY WEIGHT; COHORT STUDIES; DELAYED-ACTION PREPARATIONS; DYSKINESIA, DRUG-INDUCED; ERECTILE DYSFUNCTION; EUROPE; FEMALE; HUMANS; LIBIDO; MALE; MIDDLE AGED; ODDS RATIO; OUTPATIENTS; PROLACTIN; SCHIZOPHRENIA; SEXUAL DYSFUNCTION, PHYSIOLOGICAL; TREATMENT OUTCOME;

EID: 67649286479     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2009.03.003     Document Type: Article

References (35)

1. Allison D.B., Mentore J.L., Heo M., Chandler L.P., Cappelleri J.C., Infante M.C., and Weiden P.J. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am. J. Psychiatry 156 (1999) 1686-1696
2. Allison D.B., Mackell J.A., and McDonnell D.D. The impact of weight gain on quality of life among persons with schizophrenia. Psychiatr. Serv. 54 (2003) 565-567
3. Basson B.R., Kinon B.J., Taylor C.C., Szymanski K.A., Gilmore J.A., and Tollefson G.D. Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol or risperidone. J. Clin. Psychiatry 62 (2001) 231-238
4. Bobes J., Garca-Portilla M.P., Rejas J., Hern Ndez G., Garcia-Garcia M., Rico-Villademoros F., and Porras A. Frequency of sexual dysfunction and other reproductive side-effects in patients with schizophrenia treated with risperidone, olanzapine, quetiapine, or haloperidol: the results of the EIRE study. J. Sex. Marital. Ther. 29 (2003) 125-147
5. Brecher M., Leong R.W., Stening G., Osterling-Koskinen L., and Jones A.M. Quetiapine and long-term weight change: a comprehensive data review of patients with schizophrenia. J. Clin. Psychiatry 68 (2007) 597-603
6. Correll C.U., Leucht S., and Kane J.M. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am. J. Psychiatry 161 (2004) 414-425
7. David S.R., Taylor C.C., Kinon B.J., and Breier A. The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia. Clin. Ther. 22 (2000) 1085-1096
8. Guy G. Clinical Global Impression. ECDEU Assessment Manual for Psychopharmacology (1976), National Institute of Mental Health, Rockville, Maryland revised
9. Halbreich U., Kinon B.J., Gilmore J.A., and Kahn L.S. Elevated prolactin levels in patients with schizophrenia: mechanisms and related adverse effects. Psychoneuroendocrinol. 28 Suppl 1 (2003) 53-67
10. Haro J.M., Edgell E.T., Frewer P., Alonso J., Jones P.B., and on behalf of the SOHO Study Group. The European Schizophrenia Outpatient Health Outcomes Study: baseline findings across country and treatment. Acta Psychiatr. Scand. 107 Suppl 416 (2003) 7-15
11. Haro J.M., Edgell E.T., Jones P.B., Alonso J., Gavart S., Gregor K.J., Wright P., Knapp M., and on behalf of the SOHO Study Group. The European Schizophrenia Outpatient Health Outcomes (SOHO) study: rationale, methods and recruitment. Acta Psychiatr. Scand. 107 (2003) 222-232
12. Haro J.M., Kamath S.A., Ochoa S., Novick D., Rele K., Fargas A., Rodriguez M.J., Rele R., Orta J., Kharbeng A., Araya S., Gervin M., Alonso J., Mavreas V., Lavrentzou E., Liontos N., Gregor K., Jones P.B., and on behalf of the SOHO Study Group. The Clinical Global Impression-schizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophrenia. Acta Psychiatr. Scand. 107 Suppl 416 (2003) 16-23
13. Haro J.M., Edgell E., Novick D., Alonso J., Kennedy L., Jones P.B., Ratcliffe M., and Breier A. Effectiveness of antipsychotic treatment for schizophrenia: 6-months results of the pan-European Schizophrenia Outpatient Health Outcomes (SOHO) study. Acta Psychiatr. Scand. 111 (2005) 220-231
14. Haro J.M., Suarez D., Novick D., Brown J., Usall J., Naber D., and the SOHO Study Group. Three-year antipsychotic effectiveness in the outpatient care of schizophrenia: observational versus randomized studies results. Eur. Neuropsychopharmacol. 17 (2007) 235-244
15. Hummer M., and Huber J. Hyperprolactinaemia and antipsychotic therapy in schizophrenia. Curr. Med. Res. Opin. 20 (2004) 189-197
16. Lambert M., Haro J.M., Novick D., Edgell E.T., Kennedy L., Ratcliffe M., and Naber D. Olanzapine versus other antipsychotics in actual outpatient settings: six months tolerability results from the European Schizophrenia Outpatient Health Outcomes (SOHO) study. Acta Psychiatr. Scand. 111 (2005) 232-243
17. Lieberman J.A., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., Keefe R.S., Davis S.M., Davis C.E., Lebowitz B.D., Severe J., Hsiao J.K., and Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 353 (2005) 1209-1223
18. Malik P. Sexual dysfunction in schizophrenia. Curr. Opin. Psychiatry 20 (2007) 138-142
19. McEvoy J.P., Lieberman J.A., Perkins D.O., Hamer R.M., Gu H., Lazarus A., Sweitzer D., Olexy C., Weiden P., and Strakowski S.D. Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. Am. J. Psychiatry 164 (2007) 1050-1060
20. McIntyre R.S., Mancini D.A., and Basile V.S. Mechanisms of antipsychotic-induced weight gain. J. Clin. Psychiatry 62 Suppl 23 (2001) 23-29
21. Margolese H.C., Chouinard G., Kolivakis T.T., Beauclair L., Miller R., and Annable L. Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 2: incidence and management strategies in patients with schizophrenia. Can. J. Psychiatry 50 (2005) 703-714
22. Newcomer J.W. Metabolic considerations in the use of antipsychotic medications: a review of recent evidence. J. Clin. Psychiatry 68 Suppl 1 (2007) 20-27
23. Novick D., Haro J.M., Suarez D., Vieta E., and Naber D. Recovery in the outpatient setting: 36-month results from the Schizophrenia Outpatients Health Outcomes (SOHO) Study. Schizo. Res. 108 (2009) 223-230
24. Pendlebury J., Bushe C.J., Wildgust H.J., and Holt R.I.G. Long-term maintenance of weight loss in patients with severe mental illness through a behavioural treatment programme in the UK. Acta Psychiatr. Scand. 115 (2007) 286-294
25. Peuskens J., Sienaert P., and De Hert M. Sexual dysfunction: the unspoken side-effect of antipsychotics. Eur. Psychiatry 13 Suppl 1 (1998) 23-30
26. Pierre J.M. Extrapyramidal symptoms with atypical antipsychotics: incidence, prevalence and management. Drug Saf. 28 (2005) 191-208
27. Smith S., Yeomans D., Bushe C.J.P., Eriksson C., Harrison T., Holmes R., Mynors-Wallis L., Oatway H., and Sullivan G. A well-being programme in severe mental illness. Reducing risk for physical ill-health: a post-programme service evaluation at 2 years. Eur. Psychiatry 22 (2007) 413-418
28. Sussman N. The implications of weight changes with antipsychotic treatment. J. Clin. Psychopharmacol. 23 3 Suppl 1 (2003) 21-26
29. Tarsy D., Baldessarini R.J., and Tarazi F.I. Effects of newer antipsychotics on extrapyramidal function. CNS Drugs 16 (2002) 23-45
30. Taylor D.M., and McAskill R. Atypical antipsychotics and weight gain: a systematic review. Acta Psychiatr. Scand. 101 (2000) 416-432
31. Tenback D.E., van Harten P.N., Slooff C.J., Belger M.A., van Os J., and on behalf of the SOHO Study Group. Effects of antipsychotic treatment on tardive dyskinesia: a 6-month evaluation of patients from the European Schizophrenia Outpatient Health Outcomes (SOHO) Study. J. Clin. Psychiatry 66 (2005) 1130-1133
32. Tran P.V., Hamilton S.H., Kuntz A.J., Potvin J.H., Andersen S.W., Beasley Jr. C., and Tollefson G.D. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J. Clin. Psychopharmacol. 17 (1997) 407-418
33. Turrone P., Kapur S., Seeman M.V., and Flint A.J. Elevation of prolactin levels by atypical antipsychotics. Am. J. Psychiatry 159 (2002) 133-135
34. Uçok A., Incesu C., Aker T., and Erkoç S. Sexual dysfunction in patients with schizophrenia on antipsychotic medication. Eur. Psychiatry 22 (2007) 328-333
35. Weiden P.J. EPS profiles: the atypical antipsychotics are not all the same. J. Psychiatr. Pract. 13 (2007) 13-24